CRISPR-guided Therapeutic Discovery: First-in-Class Inhibitors of CHD4 for Glioblastoma
Elmar Nurmemmedov, Ph.D.
Assistant Professor and Director of Drug Discovery
Saint John's Cancer Institute
Saint John's Health Center
Santa Monica, Calif.
In Person Seminar: CRISPR-guided Therapeutic Discovery: First-in-Class Inhibitors of CHD4 for Glioblastoma
Date: Oct. 29, 2021
Time: 11:00 a.m. - 12:00 p.m.
Archived video
About this Seminar
Glioblastoma is a highly aggressive form of brain cancer. Therapeutic intervention of glioblastoma through epigenetic shapers such as CHD4 is established as a promising avenue for clinical impact. Despite the accumulating evidence suggesting the importance of CHD4 in glioblastoma, little effort has been done to develop specific CHD4 inhibitors.
In his lab, Dr. Nurmemmedov and his team have taken a unique approach to targeting CHD4 in glioblastoma. They have designed a two-arm therapeutic discovery approach that combined tiling CRISPR screen together with rational chemical biology. The CRISPR study identified the therapeutically vulnerable sites of the CHD4 protein. On the other hand, using rigorous biology and chemistry, the team has identified several novel inhibitors of CHD4. They hypothesize that a selective CHD4 inhibitor would specifically impair tumor growth while sparing healthy cells and could potentially have a therapeutic application for glioblastoma. These inhibitors demonstrate selectivity, target engagement, and unique mechanism of action. Once fully investigated, these molecules could be used to prevent therapy resistance in glioblastomas, with potential translation to the clinic.
You May Also Be Interested In...
-
Home Item
Mechanics of Convective Cell Motion , homeJan. 10, 2025, 11:00 a.m. | Michael Murrell, Ph.D., Associate Professor, Department of Biomedical Engineering and Physics, Yale University | Co-Sponsored by the Fralin Biomedical Research Institute Cancer Research Center – Roanoke
-
Home Item
The Role of Pericytes in Pulmonary Vascular Diseases , homeJan. 17, 2025, 11:00 a.m. | Vinicio de Jesus Perez, M.D., FCCP, FAHA, Assistant Professor, Wall Center Adult PH Clinic Division of Pulmonary and Critical Care Medicine, Stanford School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Center for Vascular and Heart Research
-
Home Item
Neural Circuits for Social Behaviors , homeJan. 24, 2025, 11:00 a.m. | Marcelo de Oliveira Dietrich, M.D., Ph.D., Associate Professor, Department of Comparative Medicine and Neuroscience, Yale School of Medicine | Co-Sponsored by the Center for Neurobiology Research, Fralin Biomedical Research Institute
-
Home Item
The Role of Exercise-Induced Blood Factor in Partial Reversal of Age-Related Loss of Plasticity in the Brain , homeJan. 31, 2025, 11:00 a.m. | Saul Villeda, Ph.D., Associate Professor, Chair, Department of Biomedical Science, University of California, San Francisco | Co-Sponsored by the Center for Exercise Medicine Research, Fralin Biomedical Research Institute
-
Home Item
Psychosocial Adjustment to Disability and Disability Identity Development , homeFeb. 14, 2025, 11:00 a.m. | Anjali Forber-Pratt, Ph.D., Director of Research, American Association on Health and Disability | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research
-
Home Item
How Big Med Drives Rising Healthcare Costs and What to Do About It , homeFeb. 20, 2025, 5:30 p.m. (Reception at 5 p.m.) | Vivian Ho, Ph.D., James A. Baker III Institute Chair in Health Economics, Baker Institute for Public Policy, Rice University | Maury Strauss Distinguished Public Lecture